Advertisement
Legal/Regulatory
Subscribe to Legal/Regulatory

The Lead

Funding to Tame Ebola Outbreak Falls Short

October 30, 2014 8:59 am | by Michael Kunzelman and Holbrook Mohr - Associated Press | News | Comments

The nation's preparedness effort to fight outbreaks of Ebola and other infectious diseases has been under-funded and lacking in political will and commitment. Read more...               

Amgen Plans More Job Cuts

October 28, 2014 12:50 pm | News | Comments

The world's biggest biotech drugmaker said that it plans to eliminate an additional 600 to 1,100...

Medical Pot Dilemma: Where to Get the First Seeds?

October 27, 2014 12:17 pm | by Carla K. Johnson - Associated Press | News | Comments

As more states legalize medical marijuana, there's one stage in the process nobody wants to talk...

Valeant: We'll Bump Allergan Offer to $200 a Share

October 27, 2014 11:03 am | News | Comments

The Canadian drugmaker Valeant said it would be...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

CSL to Acquire Novartis Influenza Vaccine Business

October 27, 2014 10:51 am | News | Comments

CSL Limited announced that it has agreed to acquire Novartis’ global influenza vaccine business for $275 million. The business will be combined with CSL’s subsidiary, bioCSL. Read more...

Newly Released Dallas Nurse to Meet With Obama

October 24, 2014 1:23 pm | by Jessica Gresko - Associated Press | News | Comments

 A nurse who caught Ebola while caring for the patient diagnosed in Dallas was released from a hospital Friday. Read more...                      

Arbor Pharmaceuticals Announces FDA New Drug Approval

October 24, 2014 12:40 pm | News | Comments

Arbor Pharmaceuticals announced that the FDA) has approved its New Drug Application (NDA) for Sotylize (sotalol hydrochloride) oral solution. Read more...                                      

Advertisement

Baxter Announces FDA Approval For New Hemophilia Drug

October 24, 2014 12:27 pm | News | Comments

Baxter International Inc. announced that the FDA has approved Obizur for the treatment of bleeding episodes in adults with acquired hemophilia A. Read more...                           

NIH Announces Grants for Frontotemporal Degeneration Research

October 23, 2014 1:44 pm | News | Comments

The National Institutes of Health will award three large, five-year projects on a specific form of dementia, known as frontotemporal because of the areas of the brain that are affected. Read more...

Pfizer Wins Patent Case in Delaware District Court

October 23, 2014 12:42 pm | News | Comments

Pfizer Inc. announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering Sutent (sunitinib malate) capsules. Read more...           

Eli Lilly Adds $375M to Zymeworks Partnership

October 23, 2014 9:52 am | News | Comments

Eli Lilly and Zymeworks said they are expanding a cancer drug development partnership. Read more...                                                   

Sutro BioPharma and Celgene Announce New Collaboration Plan

October 23, 2014 9:41 am | News | Comments

Sutro Biopharma announced it has entered into a strategic collaboration and option agreement with Celgene Corporation to discover and develop multispecific antibodies and antibody drug conjugates. Read more...                

Advertisement

U.S. to Track Everyone Coming from Ebola Nations

October 23, 2014 9:26 am | by Mike Stobbe - AP Medical Writer | News | Comments

All travelers who come into the U.S. from three Ebola-stricken West African nations will now be monitored for three weeks. Read more...                     

PhosImmune, PureMHC Working Together on Cancer Immunotherapies

October 22, 2014 1:28 pm | News | Comments

PhosImmune Inc. and PureMHC LLC announced they have entered into a license and collaboration agreement to develop novel antibody-based immunotherapies designed to target cancers. Read more...

Biogen Slides as MS Drug Linked to Inflammation

October 22, 2014 1:20 pm | News | Comments

Shares of Biogen Idec slumped 8% after the pharmaceutical said a patient who took its newest multiple sclerosis drug suffered a brain inflammation and later died. Read more...                            

Third Point Urges Amgen to Consider Breakup

October 22, 2014 12:49 pm | News | Comments

A hedge fund run by a famed investor said it has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. Read more....               

Study Finds Drugs Still in Recalled Supplements

October 22, 2014 11:48 am | by Lindsey Tanner, AP Medical Writer | News | Comments

Dietary supplements containing potentially dangerous prescription drug ingredients may still be for sale even years after safety recalls, a study found. Read more...                              

Advertisement

Actavis Signs Option to Acquire Rhythm Subsidiary

October 22, 2014 10:24 am | News | Comments

Actavis plc, a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health Inc. Read more...

12,000 Boxes of Pain Relief Tablets Are Being Recalled

October 22, 2014 10:20 am | News | Comments

12,000 boxes of pain relief tablets sold at are being recalled because the cartons contain a different medication that could cause allergic reactions. Read more...                 

Johnson & Johnson Announces New Spending Plan for Ebola Vaccine

October 22, 2014 10:05 am | News | Comments

Johnson & Johnson announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. Read more...                    

AbbVie to Pay Shire $1.64B Fee Over Nixed Merger

October 21, 2014 10:13 am | News | Comments

AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee. Read more...                            

Anti-Abuse Label Approved for Painkiller Embeda

October 20, 2014 11:45 am | News | Comments

The U.S. Food and Drug Administration (FDA) says it has approved new labeling for another opioid designed to limit painkiller abuse. Read more...                                 

Amgen Files Lawsuit Against Sanofi, Regeneron for Patent Infringement

October 17, 2014 12:57 pm | News | Comments

Amgen announced that it filed a lawsuit against Sanofi and Regeneron Pharmaceuticals, Inc. for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. Read more...

FDA Votes to Keep Boxed Warning on Chantix

October 17, 2014 10:26 am | News | Comments

Federal health advisers say a bold-letter warning about suicide risks with Pfizer's Chantix should remain on the anti-smoking drug until it can reevaluated based on new, rigorous study information. Read more...

AbbVie Sours on $55B Shire Deal After Tax Changes

October 16, 2014 10:13 am | News | Comments

AbbVie's board is telling shareholders vote against its own $55 billion takeover bid for the Irish drugmaker Shire after the U.S. made reincorporating overseas a less lucrative tax maneuver. Read more...

NIH Awards $640,000 to Improve Diagnosis of Diseases

October 16, 2014 9:52 am | News | Comments

A two-year grant from the NIH will fund work by a Purdue Research Park-based company to improve methods to screen blood plasma samples for biomarkers, which are measurable indicators of a disease, to expedite diagnosis and treatment. Read more...

FDA: Little Evidence to Drop Chantix Boxed Warning

October 15, 2014 1:22 pm | by Matthew Perrone, AP Health Writer | News | Comments

Federal regulators say Pfizer has provided low-quality evidence to support its request to remove a bold-letter warning from its anti-smoking drug Chantix about suicidal behavior. Read more...

Shire Says AbbVie Should Proceed with $55B Buyout

October 15, 2014 1:05 pm | by Tom Murphy | News | Comments

The drugmaker Shire wants AbbVie to stick with its roughly $55 billion acquisition bid, and it is reminding its U.S. counterpart of the hefty breakup fee it could receive if things don't work out. Read more...

Ex-Financial Analyst at Merck Faces Insider Trading Charge

October 15, 2014 12:43 pm | News | Comments

A former senior finance analyst at Merck & Co. is facing an insider trading charge after authorities said that he passed secrets to a friend he met at college that earned $722,000 in illegal profits. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading